Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Servier
Servier
Ohio State University Comprehensive Cancer Center
Zhejiang University
Gruppo Italiano Malattie EMatologiche dell'Adulto
National Cancer Institute (NCI)
Massachusetts General Hospital
University of Maryland, Baltimore
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
Stanford University
University of Pittsburgh
Massachusetts General Hospital
University of Pittsburgh
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Washington University School of Medicine
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins